AFP and hepatocellular carcinoma: Therefore, we aimed to evaluate the diagnostic performance of individual biomarkers (AFP, AFP-L3, and DCP) and composite scoring models (GALAD, GAAP, ASAP, aMAP, and Doylestown) in a well-characterized cohort of patients with chronic liver disease (CLD) at risk of HCC.